iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-302-3550650
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date5/8/2020 (Estimated)
OptionableNot Optionable
Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions
What is Ibio's stock symbol?
Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."
When did Ibio's stock split? How did Ibio's stock split work?
Ibio shares reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.
When is Ibio's next earnings date?
Has Ibio been receiving favorable news coverage?
News stories about IBIO stock have trended positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ibio earned a news impact score of 3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Ibio.
Who are some of Ibio's key competitors?
Some companies that are related to Ibio include Tiziana Life Sciences (TILS), Kazia Therapeutics (KZA), Mereo BioPharma Group (MPH), Medicure (MPH), Noxopharm (NOX), Scancell (SCLP), Ceapro (CZO), Actinogen Medical (ACW), Ixico (IXI), Nuformix (NFX), Oragenics (OGEN), Oragenics (OGEN), Memphasys (MEM), Prana Biotechnology (PBT) and Bionomics (BNO).
What other stocks do shareholders of Ibio own?
Who are Ibio's key executives?
Ibio's management team includes the folowing people:
- Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)
- Mr. Robert L. Erwin, Pres (Age 66)
- Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)
- Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)
- Dr. Renato Lobo, Chief Medical Officer
Who are Ibio's major shareholders?
Which institutional investors are buying Ibio stock?
How do I buy shares of Ibio?
Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ibio's stock price today?
One share of IBIO stock can currently be purchased for approximately $0.31.
How big of a company is Ibio?
What is Ibio's official website?
How can I contact Ibio?
Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.
MarketBeat Community Rating for Ibio (NYSEAMERICAN IBIO)
MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote "Outperform" if you believe IBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
